Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:
  • Temporarily not available  
  • Page 1

NCT ID: NCT05274204 Temporarily not available - Clinical trials for Advanced or Metastatic Colorectal Cancer (mCRC)

Individual Patient Expanded Access to CA102N

Start date: n/a
Phase:
Study type: Expanded Access

This study is an individual patient expanded access protocol that the subject enrolled had completed the combination treatment of CA102N plus Lonsurf for at least 12 cycles.

NCT ID: NCT03420430 Temporarily not available - Clinical trials for Advanced Stage Cancer (Solid Tumor Disease for 4 Patients)

Expanded Access to Provide GL-ONC1 for the Treatment of Advanced Cancers With No Standard of Care

Start date: n/a
Phase:
Study type: Expanded Access

GL-ONC1 expanded access is for patients who are ineligible for an ongoing GL-ONC1 clinical trial. Expanded access is intended to treat individual patients with advanced stage cancers, including blood cancer, with no standard of care options for treatment. Potential patients will be evaluated individually depending on GL-ONC1 product supply.

NCT ID: NCT02606929 Temporarily not available - Multiple Sclerosis Clinical Trials

Use of Well Known Drugs for New Destination - MS Improvement (MSNT)

MSNT
Start date: January 2015
Phase: Phase 0
Study type: Expanded Access

The purpose of this expanded access retrospective study is to determine whether tetracyclines, statins and antimycotics are effective in improvement of life and health condition in the treatment of multiple sclerosis due to autoimmune disease (MS) in all his forms, specially in patients that show no response to commonly used treatments

NCT ID: NCT01406535 Temporarily not available - Clinical trials for Coronary Artery Disease

Improvement of Myocardial Blood Flow by PhosphoDiesterase 5 Inhibition in Coronary Artery Disease

SYDNEY
Start date: n/a
Phase: N/A
Study type: Expanded Access

The aim of this study is to prospectively investigate if intermittent Phosphodiesterase 5 inhibition for 15 weeks improves myocardial perfusion by angiogenesis in patients with therapy refractory myocardial ischemia due to coronary artery disease judged to be unsuitable for surgical or percutaneous revascularisation. For proof of efficacy the following tests will be performed at baseline and one day and 4 weeks after discontinuation of therapy: Exercise tolerance will be evaluated by bicycle exercise testing. Blood tests will be performed to evaluate markers of angiogenesis (endothelial progenitor cells, vascular endothelial growth factor, basic fibroblast growth factor). The improvement of myocardial perfusion will be tested functionally as increase of coronary flow reserve by positron emission tomography. Moreover, changes in ventricular function, symptoms and quality of life will be assessed.